Ambu stock
Price history
+7.67% over the period1 year: from kr 85.35 (November 17, 2025) to kr 91.90 (November 16, 2026), +7.67%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 16, 2026 | kr 91.90 |
| October 30, 2026 | kr 81.20 |
| September 30, 2026 | kr 68.95 |
| August 31, 2026 | kr 71.15 |
| July 31, 2026 | kr 72.35 |
| June 30, 2026 | kr 61.00 |
| May 29, 2026 | kr 67.40 |
| April 30, 2026 | kr 63.05 |
| March 31, 2026 | kr 68.40 |
| February 27, 2026 | kr 79.50 |
| January 30, 2026 | kr 85.10 |
| December 30, 2025 | kr 88.00 |
| November 28, 2025 | kr 87.30 |
| November 17, 2025 | kr 85.35 |
At a glance
The company
Develops, manufactures and sells medical technology for endoscopy, anaesthesia, neurology, cardiology and emergency care
Latest results
Quarter to September 30, 2026 · EPS kr 0.93 (estimate kr 0.85)
Next event
Dividend
TickerLandia's take on Ambu
- Cheaper than usual relative to earnings: P/E on the latest fiscal year 40 vs a median of 114 over its last 10 fiscal years.
- Pricier than similar companies: trailing 12-month P/E 38 vs 30 (+25%) in a group of 10.
- Strong point: Growth (80/100 in its group). Weak point: Dividend (10/100).
- “Below historical valuation” (Denmark): No. 1 of 4.
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−1.45% from the 52-week high
Analysts · 8 analysts
Average targetkr 95.04+3.41% vs. price
Buy 2 · Hold 5 · Sell 1 · Hold
TickerLandia Fingerprint: Ambu
Compared with similar companies: very low dividend, very high risk, and very high growth.
Financials and price compared with 31 companies in the medical devices industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricehigh66
How much it costs relative to what it produces.
Metric Value Position in group Forward P/E 23.0 62 Price/sales 3.58 63 P/E (trailing 12 months) 36.8 71 EV/EBITDA 23.5 82 Price/book 3.71 53 Profitabilitylow38
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 60.1% 44 Net margin 9.9% 44 ROE 10.5% 37 ROA 6.7% 47 Operating margin 13.2% 18 Earnings stabilitylow37
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 4.2% 18 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 56 Growthvery high80
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +10.75% 66 Revenue growth (year over year) +16.00% 85 Earnings growth (year over year) +116.70% 89 Financial strengthhigh72
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −0.34 78 Interest coverage 26.1 58 Debt/equitycounts in reverse: lower means more financial strength 0.09 79 Current ratio 2.35 73 Dividendvery low10
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years 2 years 12 Payout ratio 16.9% 7 Dividend yield 0.6% 12 Market momentumstrong69
How the stock has moved compared with the market.
Metric Value Position in group 1-year return +6.76% 44 Distance from 200-day average +28.03% 95 Riskvery high86
How much the price swings.
Metric Value Position in group Maximum drawdown (12 months) 35.5% 80 Volatility (60 days) 48.6% 91
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Ambu is cheaper than in the past and pricier than similar companies
On the latest fiscal year's earnings (2025), Ambu's P/E today is 40.3, below the median of its last 10 fiscal years (114.4; between 40.6 and 193.7 from 2016 to 2025). Ambu's P/E (trailing 12 months): 38.0, +25% against the median of a group of 10 similar companies (30.3).
Compared with 10 similar companies
| Metric | Ambu | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 38.0 | Middle | |
| Forward P/E | 23.9 | Middle | |
| Operating margin | 13.2% | Low | |
| ROE | 10.5% | Middle | |
| Debt/equity | 0.09 | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Ambu. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
kr 1.64B
Latest quarter · Q2 2026
Net income
kr 156M
Latest quarter · Q2 2026
Quarterly net margin
9.5%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- kr 23.99B
- P/E
- 38.0
- EPS
- kr 2.42
- Volume
- 236.96K
- Daily trading
- €9.39M
- Dividend yield
- 0.45%
How Ambu is changing
All resultsRevenue grew 11.1% a year on average over the last 5 years
Operating margin rose from 2.7% to 13.0%
Profits turn into cash: free cash flow equal to 182% of net income
Returns
Ambu returns with dividends
kr 1,000 invested in Ambu 5 years ago, on November 16, 2021, would be worth kr 504 today with dividends reinvested: −49.58% in total, −12.80% per year. On price alone it would be kr 499 (−50.07%).
| Period | Ambu | kr 1,000 becomes |
|---|---|---|
| 1 month | +17.29% | kr 1,173 |
| 6 months | +47.16% | kr 1,472 |
| Year to date | +4.43% | kr 1,044 |
| 1 year | +8.18% | kr 1,082 |
| 3 years | +4.01% | kr 1,040 |
| 5 years | −49.58% | kr 504 |
| 10 years | +55.95% | kr 1,560 |
From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment
The chart in detail
Ambu: technical analysis
Ambu shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 74.1% below its all-time closing high (kr 355.40, April 27, 2021).
- Trend
- No clear trend
- RSI (14 sessions)
- 76
- Above 70: a strong rise in a short time
- vs 200-session average
- +28.32%
Active signals
RSI above 70: the stock has risen a lot in a short time.
since November 13, 2026
Support and resistance
Price areas where Ambu has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistancekr 92.70+0.87%2 touches, last on November 5, 2026
- Last pricekr 91.90
- Supportkr 89.04−3.11%4 touches, last on February 4, 2026
- Supportkr 86.25−6.15%2 touches, last on January 5, 2026
- Supportkr 85.00−7.51%3 touches, last on January 20, 2026
Volatility and risk
- Volatility (60 sessions, annualised)
- 48.5%
- Largest fall in the last year
- −35.45%
In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Ambu: seasonality
Average monthly price change over 23 years
Over the last 23 years, the strongest month for Ambu has been December: +6.58% on average, positive in 17 years out of 22. The weakest has been September: −2.06% on average, positive in 9 years out of 23. November, the current month, has been positive in 15 years out of 22 (+2.43% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +5.94% | +7.49% | 18 of 22 |
| February | +1.68% | −1.31% | 10 of 22 |
| March | +1.26% | +0.50% | 12 of 23 |
| April | +4.04% | +3.96% | 15 of 23 |
| May | +2.70% | +1.77% | 13 of 23 |
| June | −1.90% | −1.39% | 10 of 23 |
| July | +2.08% | +0.75% | 13 of 23 |
| August | −0.91% | −1.55% | 9 of 23 |
| September | −2.06% | −2.16% | 9 of 23 |
| October | +2.02% | −1.15% | 10 of 23 |
| November | +2.43% | +4.05% | 15 of 22 |
| December | +6.58% | +4.56% | 17 of 22 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Ambu and its competitors
Endoscopy products lead the company's range, covering bronchoscopes, video laryngoscopes, gastroscopes, cystoscopes and ureteroscopes, along with the displaying and processing units that accompany them. The company also sells neurology devices, including EEG and EMG electrodes and intraoperative monitoring products, plus ECG electrodes for cardiology. Airway management and anaesthesia tubes, masks and resuscitators, emergency care equipment and training manikins complete the offering, which is sold in North America, Europe and other international markets.
- Headquarters
- Ballerup, Denmark
- Employees
- 4,664
- Founded
- 1937
- Chief executive
- Britt Jensen
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| AmbuAMBU.B | $3.55B | 13.2% | 38.0 | +47.16% |
| Medacta GroupMOVE | $2.57B | 15.2% | 30.2 | −22.11% |
| GN Store NordGN | $2.57B | 10.9% | 90.2 | +25.93% |
| ElektaEKTA.B | $2.37B | 9.2% | — | +15.05% |
| SectraSECT.B | $6.17B | 20.6% | 99.9 | +28.26% |
| ChemoMetecCHEMM | $1.85B | 49.8% | 63.0 | +123.20% |
Same industry or related industries, similar size. Compare Ambu with its competitors · Full profile
